Neutralization of human T-lymphotropic virus type III by sera of AIDS and AIDS-risk patients

Weiss, Robin A.; Clapham, Paul R.; Cheingsong-Popov, Rachanee; Dalgleish, Angus; Carne, Christopher; Weller, I. V. D.; Tedder, Richard S.

doi:10.1038/316069a0

Cited by 431 publications

(164 citation statements)

References 30 publications

Supporting

Mentioning

162

Contrasting

Order By: Relevance

“…HIV+ sera exert group-specific neutralizing activities (22)(23)(24). Recent reports (25,26) also demonstrated that the group-specific neutralizing activities disappeared after absorption ofthe sera on gpl60.…”

Section: Resultsmentioning

confidence: 99%

Evidence for non-V3-specific neutralizing antibodies that interfere with gp120/CD4 binding in human immunodeficiency virus 1-infected humans.

Kang

Nara

Chamat

et al. 1991

Proc. Natl. Acad. Sci. U.S.A.

View full text Add to dashboard Cite

Total anti-gpl20 antibodies (total anti-gpl20 Abs) were purified from a pool of four human immunodeficiency virus-positive (HIV+) sera by affinity chromatography on a gp120sF2-Sepharose column and exhibited both type-and group-specific neutralizing activities. To dissect the epitope specificity of the group-specific neutrazing antibodies, CD4 attachment site-specific antibodies (CD4-site Abs) were isolated from total anti-gpl20 Abs by using a CD4-blocked gpl2OsF2-Sepharose column. The CD4-site Abs exhibited group-specific neutralizing activities. Another approach to dissecting typeand group-specific neutralizing activities of total anti-gpl20 Abs was to separate the third variable region (V3)-specific antibodies (V3-region Abs) from non-V3-region-speciflc antibodies (non-V3 Abs). The results indicated that V3-region Abs exhibited type-specific neutralizing activities, whereas non-V3 Abs exhibited group-specific neutralizing activities. By comparing the neutralizing activities of V3-region Abs to those of non-V3 Abs, we concluded that V3-region Abs are more effective than non-V3 Abs in neutralizing a specific HIV isolate. Collectively, this study indicates that group-specific neutralizing anti-gpl20 antibodies are specific for the CD4 attachment site.Although the precise role of the third variable region (V3) of gpl20 in virus infection is still in question, antibodies to this region elicited by vaccination or infection neutralize virus infectivity by interfering with a postbinding event (1-4). Furthermore, antibodies to this region exert their primary neutralizing effects on the virus strain used in immunization (5-8) and have been called "type-specific neutralizing antibodies." Under some circumstances, cross-neutralizing antibodies to the V3 domain have been observed (9). The hypervariability of the envelope region outside as well as within the V3 domain suggests that HIV mutants emerge over time that escape V3 type-specific neutralizing antibodies (10, 11). Primary, secondary, and tertiary structure of the V3-region molecule are important in antibody binding and neutralization (12, 13). Since all known HIV isolates retain the ability to infect CD4+ cells despite considerable sequence variation within gpl20, it has been suggested that the CD4 attachment site on gp120 consists of conserved regions (14,15). Antibodies binding to this CD4 attachment site are expected to block infection of a majority (if not all) of HIV isolates by interfering with the interaction with CD4+ cells. Antibodies specific against this region have been detected in the sera ofHIV-infected humans (16)(17)(18). A recent report (19) described a human monoclonal antibody derived from a seropositive patient that is specific for the CD4 attachment site and neutralizes multiple HIV isolates. To date no attempts have been made to our knowledge to purify these antibodies and directly correlate their activity and concentrations associated with neutralization of multiple strains of HIV-1.This study was undertaken to gain a better understand...

show abstract

Section: Resultsmentioning

confidence: 99%

Evidence for non-V3-specific neutralizing antibodies that interfere with gp120/CD4 binding in human immunodeficiency virus 1-infected humans.

Kang

Nara

Chamat

et al. 1991

Proc. Natl. Acad. Sci. U.S.A.

View full text Add to dashboard Cite

show abstract

“…In this reaction, specific antibodies bind to HIV antigens on the surface of infected cells, which are then killed by Fc receptor-positive effector cells [13]. HIV-specific antibodies from infected individuals have also been found to neutralize viral infectivity in vitro [14,15]. Although the in vivo role is not fully understood, it is likely that neutralizing antibodies are most important in the anti-viral defence.…”

Section: Introductionmentioning

confidence: 99%

Antibody-dependent cellular cytotoxicity and neutralizing activity in sera of HIV-1-infected mothers and their children

Broliden

Sievers

Tovo

et al. 1993

Clinical and Experimental Immunology

View full text Add to dashboard Cite

SUMMARYThe prognostic and protective role of antibodies mediating cellular cytotoxicity (ADCC) and neutralization was evaluated in sera of HIV-1-infected mothers and their consecutively followed children. The presence and titres of ADCC mediating and/or neutralizing antibodies in maternal sera did not predict HIV-1 infection in their respective children. No significant diflFerence in the sera from the children was seen when comparing the presence of neutralizing antibodies between the uninfected and infected children. Stratification of the infected group according to clinical status revealed differences. Only one of 24 AIDS patients had a high neutralizing titre against IIIB. Four patients had a very low titre and the remaining had no detectable neutralizing antibodies at all. In contrast, 10/17 infected non-AIDS children had neutralizing antibodies. Similarly, no significant difference was seen when comparing the presence of ADCC-mediating antibodies between the uninfected and the infected group of children. However, a significantly higher frequency of ADCC was seen in the seropositive non-AIDS children compared with the AIDS children. This study clearly shows that the presence of antibodies mediating ADCC and neutralization in infected children, 0-2 years old, is associated with a better clinical status and delayed disease progression.

show abstract

“…Robert-Guroff et al 1985, Weiss et al 1985. In the course of the last three years, however, the high protection obtained in monkeys infused with anti-HIV-1 monoclonal antibodies has increased interest in HIV-1 neutralization (Baba et al 2000, Mascola et al 2000, Nishimura et al 2002, Ferrantelli et al 2004.…”

mentioning

confidence: 99%

Human immunodeficiency virus type 1 neutralization by plasma from B or F genotype infected individuals

Bongertz

Teixeira

Grinztejn

et al. 2005

Mem. Inst. Oswaldo Cruz

View full text Add to dashboard Cite

Anti-human immunodeficiency virus type 1 (HIV-1) "binding antibodies" (antibodies capable of binding to synthetic peptides or proteins) occur throughout HIV-1 infection, are high-titered and highly cross-reactive, as confirmed in this study by analyzing plasma from B and F genotype HIV-1 infected individuals. Plasma from individuals infected with clade F HIV-1 displayed the most frequent cross-reactivity, in high titers, while Bbr plasma showed much higher specificity. Similarly, neutralization of a reference HIV-1 isolate (HIV-1 MN) was more frequently observed by plasma from F than B genotype infected individuals. No significant difference was seen in neutralization susceptibility of primary B, Bbr or F clade HIV-1 by plasma from individuals infected with the classical B (GPGR) or F HIV-1, but Bbr (GWGR) plasma were less likely to neutralize the F genotype primary HIV-1 isolates. The data indicate that both B and F genotype derived vaccines would be equally effective against B and F HIV-1 infection, with a slightly more probable effectiveness for F than B genotype. Although the Bbr variant appears to induce a much more specific humoral immune response, the susceptibility in neutralizing the Brazilian HIV-1 B genotype Bbr variant is similar to that observed with the classical B genotype HIV-1

show abstract

Neutralization of human T-lymphotropic virus type III by sera of AIDS and AIDS-risk patients

Cited by 431 publications

References 30 publications

Evidence for non-V3-specific neutralizing antibodies that interfere with gp120/CD4 binding in human immunodeficiency virus 1-infected humans.

Evidence for non-V3-specific neutralizing antibodies that interfere with gp120/CD4 binding in human immunodeficiency virus 1-infected humans.

Antibody-dependent cellular cytotoxicity and neutralizing activity in sera of HIV-1-infected mothers and their children

Human immunodeficiency virus type 1 neutralization by plasma from B or F genotype infected individuals

Contact Info

Product

Resources

About